Hibiscus Study: An oral investigational medication for SCD
Patient-friendly certified
What is this?
About the Study
The Hibiscus Study is enrolling adults and adolescents 12 to 65 years old with a clinical diagnosis of SCD. The primary purpose of the study is to evaluate the safety and effectiveness of an oral investigational medication for SCD.
Read moreParticipation information
Age
12
- 65Gender
All
Genotypes
All types of SCD
Study Information
Study type
Clinical
Interventions
Oral FT-4202
Phase
2/3
Compensation
Reimbursement for time and travel may also be available
Am I Eligible?
Requirements
You may be eligible to participate in this study if you:- Patient has a confirmed diagnosis of sickle cell disease
- Have experienced at least 2 pain episodes (vaso-occlusive crises) within the past 12 months, but not more than 10
- Be willing and able to follow all study requirements and study visit schedules
- Additional eligibility criteria will apply, and a study doctor will explain this information to you
Restrictions
You can't participate in this study if you:- More than 10 vaso-occlusive crises within the past 12 months
- Female who is breastfeeding or pregnant
- Known HIV positive
- Active hepatitis B or hepatitis C infection
- Severe kidney dysfunction or on chronic dialysis
- Additional eligibility criteria will apply, and a study doctor will explain this information to you